Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lapatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 18/20 | 0.99 |
| ▸ | ERBB2 known ✓ | P04626 | 17/20 | 0.99 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.87 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.87 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.87 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.87 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.87 |
| ▸ | STK10 | O94804 | 1/20 | 0.87 |
| ▸ | ABL1 | P00519 | 1/20 | 0.87 |
| ▸ | INSR | P06213 | 1/20 | 0.87 |
| ▸ | RET | P07949 | 1/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.87 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.87 |
| ▸ | SRC | P12931 | 1/20 | 0.87 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.87 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.87 |
| ▸ | CDK2 | P24941 | 1/20 | 0.87 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.87 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lapatinib SCHEMBL31732815 | 1.00 | ABCB11 (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL1374543 | 1.00 | ABCB11 (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL29866632 | 1.00 | ABCB11 (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL4926017 | 0.99 | EGFR (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL29356338 | 0.99 | EGFR (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL15408126 | 0.99 | EGFR (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL4097293 | 0.99 | EGFR (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL30680457 | 0.99 | EGFR (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL571898 | 0.99 | EGFR (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL29251597 | 0.95 | ABCB11 (0.91) | ABCB11EGFRERBB2MEN1PIK3C2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2958592-A1 | METHODS OF TREATING CANCER AND PREVENTING DRUG RESISTANCE | F. Hoffmann-La Roche AG (CH) | 2015-12-30 | — | — | EP | claimed |
| WO-2014128235-A1 | METHODS OF TREATING CANCER AND PREVENTING DRUG RESISTANCE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-08-28 | — | — | WO | claimed |
| EP-2425830-A1 | Synergistic drug combination for the treatment of cancer | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-03-07 | — | — | EP | claimed |
| EP-4067347-B1 | HETEROCYCLIC INHIBITORS OF CBP/EP300 FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-3189049-B1 | PHTHALAZINE DERIVATIVES OF FORMULA (I) AS PCAF AND GCN5 INHIBITORS FOR USE IN THE TREATMENT OF CANCER | GENENTECH INC (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-3296905-B1 | METHOD FOR IDENTIFYING NEW MARKERS | ALACRIS THERANOSTICS GMBH (DE) | 2023-11-08 | — | — | EP | disclosed |
| EP-3262036-B1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-4223770-A2 | NOVEL FUSION MOLECULES AND USES THEREOF | Foundation Medicine, Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-2914622-B1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUND MEDICINE INC (US) | 2023-06-07 | — | — | EP | disclosed |
| CN-113827596-B | Application of lapatinib and/or pharmaceutically acceptable derivatives thereof in preparation of anti-enterovirus drugs | 武汉市金银潭医院(武汉市传染病医院) | 2022-09-09 | — | — | CN | disclosed |
| US-20220169703-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2022-06-02 | — | — | US | disclosed |
| WO-2014159356-A1 | COMPOSITIONS AND METHODS FOR EPITHELIAL STEM CELL EXPANSION AND CULTURE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014139326-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014128235-A1 | METHODS OF TREATING CANCER AND PREVENTING DRUG RESISTANCE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-08-28 | — | — | WO | disclosed |
| US-20130123497-A1 | POLYMORPHIC FORMS OF LAPATINIB DITOSYLATE AND PROCESSES FOR THEIR PREPARATION | APOTEX PHARMACHEM INC. (CA) | 2013-05-16 | — | — | US | disclosed |
| EP-2560968-A1 | POLYMORPHIC FORMS OF LAPATINIB DITOSYLATE AND PROCESSES FOR THEIR PREPARATION | Apotex Pharmachem Inc. (CA) | 2013-02-27 | — | — | EP | disclosed |
| WO-2012028334-A2 | MARKER FOR SUNITINIB RESISTANCE FORMATION | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER FÖRDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2012-03-08 | — | — | WO | disclosed |
| EP-2425830-A1 | Synergistic drug combination for the treatment of cancer | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-03-07 | — | — | EP | disclosed |
| EP-2426213-A1 | Marker for sunitnib resistance formation | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-03-07 | — | — | EP | disclosed |
| EP-1792902-A1 | Processes for preparation of 5-(6-quinazolinyl)-furan-2-carbaldehydes | GLAXO GROUP LIMITED (GB) | 2007-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169703-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | EGFR 2414/4885ERBB2 1580/4885ABCB11 4482/4885 |
| US-20130123497-A1 | POLYMORPHIC FORMS OF LAPATINIB DITOSYLATE AND PROCESSES FOR THEIR PREPARATION | APOL1, APOB, BRCA1 | EGFR 35/4885ERBB2 10/4885ABCB11 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.